Low hepatitis B surface antigen levels signal minimal liver cancer risk, redefining ‘partial cure’

Researchers from National Taiwan University Hospital and Academia Sinica have identified a simple blood marker that can reliably pinpoint chronic hepatitis B (CHB) patients at negligible risk of developing liver cancer.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup